Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Quantitative Estimation of Thrombus Burden in Patients With STEMI Using Micro-Computed Tomography (QUEST-STEMI) (QUEST-STEMI)

7 juillet 2020 mis à jour par: Karagiannidis Efstratios, Aristotle University Of Thessaloniki

Quantitative Estimation of Thrombus Burden in Patients With ST Elevation Acute Myocardial Infarction (STEMI) With the Use of Micro-computed Tomography-A Methodological Approach (QUEST-STEMI)

The study aims to assess for the first time, through the application of innovative technologies (micro-CT), important characteristics of aspirated thrombi (such as their volume and their density), which might be linked to certain clinical outcomes, in patients presenting with STEMI and referred for primary Percutaneous Coronary Intervention (PCI). To this end, a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi will be developed. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume and their density will be calculated with the use of micro-CT. Having a better resolution than conventional computed tomography, micro-CT will allow us to create 3D models of aspirated thrombi from a series of x-ray projection images. These 3D models will be further analyzed in order to find the volume and the density of aspirated thrombi. Shape analysis of the surface of aspirated thrombi and potential differences in their structure will also be assessed. Correlation of these variables with clinical parameters and angiographic outcomes will be attempted.

Thus, a risk-stratification model will be developed combining:

  • Clinical and laboratory data,
  • Angiographic parameters,
  • Data regarding the volume, the density and the composition of aspirated thrombi.

This model will enable the stratification of the cardiovascular and cerebrovascular risk of patients and the identification of who will benefit from thrombus aspiration, providing a personalized approach in treating patients with STEMI.

Aperçu de l'étude

Description détaillée

Acute myocardial infarction with ST elevation (STEMI) remains one of the leading causes of mortality in developed countries, in spite of the important advances in pharmacological therapy and in mechanical reperfusion therapy. Having an important role in provoking ischemia, thrombus has been studied in many clinical trials and high thrombus burden has been proven to be an independent risk factor for stent thrombosis and for Major Adverse Clinical outcomes. However large randomized controlled trials concerning thrombus aspiration showed controversial results, providing as a whole no evidence of distinct benefits for thrombus aspiration. A possible explanation could be that aspiration was performed as a routine strategy in all of these trials, whereas these patients should be considered as a heterogeneous group and thus they should be risk-stratified. For this reason, it is of paramount importance to classify patients according to the volume of thrombus burden. The currently existing classifications of thrombus burden (the most important being those of Gibson and of Sianos) are based on visual assessment of angiographic characteristics and thus they are not reflecting the volume of the thrombi in actual, absolute numbers.

The main purpose of the study is to develop a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi in patients presenting with STEMI and referred for primary PCI. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume will be calculated with the use of micro-CT. The scanning procedure results into a series of projection images arranged in the form of image stacks which, in turn, are reformed in sections (cross section images) with the use of the NRecon (Bruker, Kontich, Belgium) software, which applies a modified algorithm of backward projection Feldkamp. The resulting sections will be combined to create the 3D models which will be further analyzed to extract useful measurements for the characteristics of the thrombi, such as for the volume and the elative density. Shape analysis on the surface and internal structure of the three-dimensional representations of the specimens will lead to the identification of the important features that can be used to estimate variability within samples and perform clustering for the significant differences between clots. In addition, possible differences in clot internal and external structure (e.g. architecture of the various cell types) will be assessed through the 3D models rendered from the stacks of images The Secondary end points of the study include the examination of the association of the aforementioned variables with the angiographic classification of thrombus burden (according to Sianos), with electrocardiographic and angiographic characteristics suggestive of poor patient prognosis and with major adverse cardiac events during the follow-up period of one year.

This method could become the gold standard for the exact measurement of thrombus burden and could be used in larger, clinically-oriented trials to help stratify patients with thrombus burden according to their risk for adverse outcomes.

Type d'étude

Observationnel

Inscription (Réel)

115

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Thessaloníki, Grèce, 54636
        • University General Hospital of Thessaloniki AHEPA

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

consecutive patients presenting with ST elevation myocardial infarction, who undergo primary PCI and thrombus aspiration

La description

Inclusion Criteria:

  • Patients presenting with symptoms of myocardial ischemia lasting for more than 30 minutes
  • Definite ECG changes indicating STEMI
  • Patients undergoing primary PCI within 12 hours from symptom onset
  • Possibility to perform thrombus aspiration
  • Age>18 years
  • Written informed consent prior to enrolment in the clinical trial

Exclusion Criteria:

  • Treatment with fibrinolytic therapy for qualifying index STEMI event
  • Patients with known intolerance to aspirin, ticagrelor or heparin
  • Patients with active internal bleeding
  • Patients with a recent history of intracranial hemorrhage

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: Cas uniquement
  • Perspectives temporelles: Éventuel

Cohortes et interventions

Groupe / Cohorte
patients avec une faible charge de thrombus
patients avec le plus faible volume de thrombi aspiré, tel que mesuré par micro-CT
patients avec une forte charge de thrombus
les patients avec le plus grand volume de thrombi aspiré, tel que mesuré par micro-CT

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
volume of aspirated thrombus burden
Délai: 12 months
The volume of aspirated thrombi will be quantified using micro-CT.
12 months
density of aspirated thrombus burden
Délai: 12 months
The density of aspirated thrombi will be quantified using micro-CT.
12 months
MACCE-free survival
Délai: 12 months
Time between the date of diagnosis and MACCE during the follow-up period of 12 months. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
association between thrombus volume with factors from patients medical history
Délai: 12 months
Potential association of thrombus volume (as assessed using micro-ct) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
12 months
association between thrombus density with factors from patients medical history
Délai: 12 months
Potential association of thrombus density ( as assessed using micro-CT) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
12 months
Correlation of the volume of aspirated thrombus burden with the Sianos' classification of thrombus burden
Délai: 12 months
Potential correlation of the volume of aspirated thrombus burden, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored. According to Sianos' classification thrombi are classified in the following categories: G0,G1,G2,G3,G4.
12 months
Correlation of thrombus density with the Sianos' classification of thrombus burden
Délai: 12 months
Potential correlation of thrombus density, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored.
12 months
association of thrombus volume with electrocardiographic outcomes suggestive of poor patient prognosis
Délai: 12 months
Potential association of thrombus volume as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
12 months
association of thrombus density with electrocardiographic outcomes suggestive of poor patient prognosis
Délai: 12 months
Potential association of thrombus density as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
12 months
association of thrombus volume with post-procedural Thrombolysis in Myocardial Infarction(TIMI) flow
Délai: 12 months
Potential association of thrombus volume as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
12 months
association of thrombus density with post-procedural TIMI flow
Délai: 12 months
Potential association of thrombus density as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
12 months
association of thrombus volume with myocardial blush grade
Délai: 12 months
Potential association of thrombus volume as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
12 months
association of thrombus density with myocardial blush grade
Délai: 12 months
Potential association of thrombus density as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
12 months
association of thrombus volume with distal embolization .
Délai: 12 months
Potential association of thrombus volume as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
12 months
association of thrombus density with distal embolization .
Délai: 12 months
Potential association of thrombus density as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
12 months
association of thrombus volume with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Délai: 12 months
Potential association of thrombus volume, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months
association of thrombus density with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Délai: 12 months
Potential association of thrombus density, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Georgios Sianos, MD,PhD, FESC, Associate Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Chercheur principal: Efstratios Karagiannidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
  • Chercheur principal: Charalambos Karvounis, MD,Phd, Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Chercheur principal: George Giannakoulas, MD,Phd, Assistant Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Chercheur principal: Christos Arvanitidis, Phd, Director of Research, Hellenic Center for Marine Research
  • Chercheur principal: Ioannis Vizirianakis, PharmD, PhD, Associate Professor, School of Pharmacy, Aristotle University of Thessaloniki
  • Chercheur principal: James S Michaelson, MD,Phd, Associate Professor, Department of Pathology, Harvard Medical School
  • Chercheur principal: Kleoniki Keklikoglou, MSc, HELLENIC CENTER FOR MARINE RESEARCH
  • Chercheur principal: Ivelin Samra, MD, Head of cardiology department at MHAT"Hadzy Dimityr" Sliven
  • Chercheur principal: Nikolaos Konstantinidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
  • Chercheur principal: Georgios Sofidis, MD,Phd, Aristotle University Of Thessaloniki

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

25 janvier 2018

Achèvement primaire (Réel)

7 juillet 2020

Achèvement de l'étude (Réel)

7 juillet 2020

Dates d'inscription aux études

Première soumission

25 janvier 2018

Première soumission répondant aux critères de contrôle qualité

5 février 2018

Première publication (Réel)

12 février 2018

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

8 juillet 2020

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 juillet 2020

Dernière vérification

1 juillet 2020

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

Indécis

Description du régime IPD

The decision to share or not individual participant data with other researchers will depend on the purpose and the scope of the proposed research

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner